Tumor deficiency

Gradual diminution of 004 T-lymphocytes from the peripheral blood is the most consistent feature observed in HIV infection. Because the majority of 004 cells are T-helper lymphocytes, removal leads to deficiency of cellular immunity, which depends on T-helper cells to initiate cytotoxic T-ceU killing of vims-infected cells of cancer. The loss of immune surveillance leads to the appearance of viraHy induced tumors from unopposed clonal expansion of viraHy transformed cells. Furthermore, depletion of cellular immunity leads to exaggerated viral, fungal, and proto2oal infections. 

Therapy with L-asparaginase is most successful against tumors exhibiting a deficiency in the synthesis of L-asparagine. Most normal cells exhibit a healthy capacity to synthesize this nonessential amino acid and are not damaged by exposure to L-asparaginase (23). This finding demonstrates that biochemical differences between normal and cancer cells can be exploited for successful cancer chemotherapy. 

Folic acid deficiency Hyperthermia Phenylketonuria Rheumatic disease Virilizing tumors Drugs and chemicals Androgenic chemicals Angiotensin-converting enzyme inhibitors Captopril, enalapril Antibiotics... 

The patient likely will have a history of childhood-onset GH deficiency, hypothalamic or pituitary disorder, or the presence of three or four other pituitary hormone deficiencies caused by head trauma, tumor, infiltrative diseases, surgery, or radiation therapy. 

Patient and tumor biology also affect how cancer therapy is dosed. Patients with a uridine diphosphate-glucuronosyltransferease 1A1 enzyme deficiency can have... 

Two groups demonstrated that BRCA-1- and BRCA-2-deficient cells are acutely sensitive to PARPi [11,12]. Potent inhibitors like KU0058684 (5), KU0058948 (6), and AG14361 (26) were cytotoxic at nanomolar concentrations in HR-defective cells, and displayed excellent selectivity for BRCA-1- and BRCA-2-deficient cells over wild-type cells. After 24 h of exposure, 5 elicited G2 or M phase cell cycle arrest and a tetraploid DNA content. The applicability of this discovery was revealed when BRCA-2-deficient and BRCA-2-proficient cells were injected into mice and tumors were allowed to develop. Daily treatment with 5 or 26 had no effect on the BRCA-2 wild-type cells however, when BRCA-2-deficient cells were treated with PARPi, no tumors developed. 

APPLICATION TO TUMORS WITH OTHER DNA DAMAGE REPAIR DEFICIENCIES... 

ATM-deficient cell lines were found to be sensitive to olaparib [53]. In xenograft studies using ATM-deficient Granta-519 cells, olaparib was shown to decrease tumor growth and prolong overall survival by 42%. 

Bone is one of the few tissues capable of self-regeneration during skeletal deficiency, but this regeneration is limited by the nature and size of the defect. In general, skeletal deficiency occurs as a result of trauma, tumor, bone disease, or abnormality. In the case of severe fracture, bone will not heal by itself. For this reason, artificial bone substitutes may be required to restore routine function without damaging living tissue, and the selection of the bone graft substitute is the most important factor for better performance in vivo. 

The role of N-sulfonyloxy arylamines as ultimate carcinogens appears to be limited. For N-hydroxy-2-naphthylamine, conversion by rat hepatic sulfotransferase to a N-sulfonyloxy metabolite results primarily in decomposition to 2-amino-l-naphthol and 1-sulfonyloxy-2-naphthylamine which are also major urinary metabolites and reaction with added nucleophiles is very low, which suggests an overall detoxification process (9,17). However, for 4-aminoazobenzene and N-hydroxy-AAF, which are potent hepatocarcinogens in the newborn mouse, evidence has been presented that strongly implicates their N-sulfonyloxy arylamine esters as ultimate hepatocarcinogens in this species (10,104). This includes the inhibition of arylamine-DNA adduct formation and tumorigenesis by the sulfotransferase inhibitor pentachlorophenol, the reduced tumor incidence in brachymorphic mice that are deficient in PAPS biosynthesis (10,115), and the relatively low O-acetyltransferase activity of mouse liver for N-hydroxy-4-aminoazobenzene and N-OH-AF (7,114,115). 

---